Lymphoma & Plasma Cell Disorders
Video
JULIET: CAR T cells go the distance in r/r DLBCL
SAN DIEGO – Median overall survival among patients with complete responses to CAR-T cell therapy in the JULIET trial has not been reached.
Video
Beat AML trial delivers genomic results in 7 days
SAN DIEGO – The umbrella trial, sponsored by the Leukemia & Lymphoma Society, harnesses technology to speed genomic results that could...
Conference Coverage
JULIET: CAR T cells keep trucking against DLBCL
SAN DIEGO – Median overall survival for patients with complete responses to CAR T-cell therapy was not reached through 19 months of follow-up.
Conference Coverage
FLYER: Four cycles of R-CHOP as good as six in low-risk DLBCL
SAN DIEGO – Survival outcomes were nearly identical and adverse events were lower with four versus six cycles of R-CHOP in patients with favorable...
Video
FLYER: R-CHOP 4 safer, as effective for low-risk DLBCL patients under 60
SAN DIEGO – Progression-free, event-free, and overall survival were comparable with that of patients assigned to six cycles of therapy.
News
FDA approves rituximab biosimilar for lymphoma
Truxima is the first biosimilar approved in the United States to treat non-Hodgkin lymphoma.
News
Bortezomib may unlock resistance in WM with mutations
The study tested how a bortezomib treatment combination would perform in patients with CXCR4 mutations.
News
First-line bortezomib prolongs survival in MCL
The survival benefits are promising with the addition of bortezomib, but there was no significant difference among high-risk patients.
Conference Coverage
Will quad therapy become the new standard in myeloma?
NEW YORK – Phase 2 studies have shown high response rates for four-drug combinations targeting multiple myeloma.
Conference Coverage
Real-world clues for optimal sequencing of CLL novel agents
NEW YORK – Dr. John Allan of Cornell University said
